Paul Reider - 22 Jul 2024 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRS	Stock Option (Right to Buy)	Award	$0	+40,000		$0.000000	40,000	22 Jul 2024	Common Stock	40,000	$2.41	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	On April 11, 2024 the Reporting Person was granted a performance stock option to purchase 200,000 shares of common stock, of which 40,000 of the shares vested and became exercisable on July 22, 2024 in connection with the Closing of the sale of Coherus BioSciences, Inc.'s YUSIMRY franchise.